8-K: 89bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

89bio announced its third quarter 2024 financial results, highlighting progress in its Phase 3 clinical trials and strategic leadership appointments.

Summary

• 89bio reported its financial results for the third quarter ended September 30, 2024.
• The company is progressing with its Phase 3 ENLIGHTEN program for MASH and the ENTRUST trial for SHTG.
• Topline data from the ENTRUST trial is expected in 2025.
• The company has strengthened its leadership team with key appointments to the Board and executive roles.
• 89bio secured an amended credit facility with K2 HealthVentures, providing up to $150 million in financing.
• The company drew $35 million at close and has access to an additional $35 million through June 30, 2025.
• 89bio may also draw two additional tranches totaling up to $80 million subject to certain milestones.
• As of September 30, 2024, 89bio had $423.8 million in cash, cash equivalents, and marketable securities.
• Research and development expenses were $141.4 million for the quarter, significantly up from $31.4 million in the same period last year, primarily due to a milestone payment of $81 million to BiBo.
• General and administrative expenses increased to $10.5 million from $7.9 million year-over-year.
• The company reported a net loss of $149.1 million for the quarter, compared to a net loss of $34.7 million in the same quarter of 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company is making progress in its clinical trials and has secured funding, the significant increase in R&D expenses and the substantial net loss are concerning. The company is in a high-risk, high-reward phase.

Positives

• The Phase 3 ENLIGHTEN program for MASH is progressing with patient enrollment.
• The company has strengthened its leadership team with experienced professionals.
• 89bio has secured a significant credit facility to support its operations.
• The company has a strong cash position of $423.8 million.

Negatives

• Research and development expenses significantly increased to $141.4 million due to a large milestone payment.
• The company reported a substantial net loss of $149.1 million for the quarter.
• General and administrative expenses also increased.

Risks

• The company is dependent on the success of its lead product candidate, pegozafermin.
• Clinical trial results may not be predictive of future outcomes.
• The company faces competition from other pharmaceutical companies.
• The company's ability to raise additional capital is a risk.
• The company's financial results are subject to various risks and uncertainties.

Future Outlook

The company expects topline data from the ENTRUST Phase 3 trial in SHTG in 2025 and is continuing to enroll patients in its Phase 3 ENLIGHTEN trials for MASH. The company is also pursuing potential accelerated approval in the United States and conditional approval in Europe for MASH.

Management Comments

• We continue to execute on our three pivotal Phase 3 trials for pegozafermin in MASH and SHTG, stated Rohan Palekar, CEO of 89bio.
• Building on the positive momentum from ENLIGHTEN and ENTRUST, we have made strategic additions to our Board of Directors and Executive Leadership Team, as well as bolstered our financial position with support from K2 HealthVentures.

Industry Context

89bio is operating in the competitive biopharmaceutical space, focusing on liver and cardiometabolic diseases. The company's progress in Phase 3 trials for MASH and SHTG positions it to potentially address unmet needs in these areas. The company's focus on pegozafermin, a FGF21 analog, aligns with the industry's interest in novel therapies for metabolic diseases.

Comparison to Industry Standards

• 89bio's increased R&D spending is typical for a clinical-stage biotech company advancing multiple Phase 3 trials, similar to companies like Madrigal Pharmaceuticals and Viking Therapeutics, which are also developing treatments for MASH.
• The net loss of $149.1 million is substantial, but not uncommon for companies in this stage of development, as they invest heavily in clinical trials and infrastructure. For example, companies like Intercept Pharmaceuticals have also reported significant losses during their clinical development phases.
• The $423.8 million cash position is relatively strong, providing a runway for continued operations and clinical development, which is comparable to other companies in the space with similar clinical programs.
• The credit facility with K2 HealthVentures is a common financing strategy for biotech companies, similar to how companies like Alnylam Pharmaceuticals have used debt financing to support their operations.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the increased net loss, but encouraged by the progress in clinical trials and the secured funding.
• Employees may be impacted by the increased headcount and the company's growth.
• Patients with MASH and SHTG may benefit from the potential development of new therapies.
• Creditors are impacted by the new credit facility with K2 HealthVentures.

Next Steps

• Continue enrollment in the Phase 3 ENLIGHTEN trials for MASH.
• Continue enrollment in the Phase 3 ENTRUST trial for SHTG.
• Present new analyses of data from the ENLIVEN Phase 2b trial at the AASLD meeting in November 2024.
• Report topline data from the ENTRUST trial in 2025.
• Potentially pursue accelerated approval in the United States and conditional approval in Europe for MASH.

Key Dates

Keywords

89bio, pegozafermin, MASH, SHTG, clinical trials, biopharmaceutical, financial results, R&D expenses, net loss, K2 HealthVentures, ENLIGHTEN, ENTRUST